Background {#Sec1}
==========

Cystic echinococcosis (CE) is a parasitic zoonosis, listed among the neglected diseases for which the World Health Organization (WHO) advocates concentrated control efforts \[[@CR1]\]. Human CE is caused by the tapeworm *Echinococcus granulosus* (*sensu lato*) species complex, naturally transmitted between canids (mainly the domestic dog) and ungulates (mainly livestock, especially sheep) in a faecal-oral and predator-prey cycle. After the accidental ingestion of infective eggs by humans, the parasite develops as fluid-filled cysts (metacestodes) in organs and tissues, mainly the liver and lungs \[[@CR2]\]. CE is mostly endemic in rural areas of China, Central Asia, South America, the Mediterranean, East Africa, and Australia, where livestock breeding is practiced \[[@CR3]\].

Current CE burden estimates indicate globally about 300,000 disability adjusted life years, and an annual cost of about 200 million USD for human treatment of CE \[[@CR4]\]. However, these estimates, based on highly heterogeneous and incomplete data sources, are largely underestimated, resulting in misperception of the magnitude of CE public health impact. Figures actually triplicate when accounting for estimated underreporting of cases reaching medical attention, not taking into consideration the disease burden carried by infected people not accessing health care \[[@CR4]\]. Underreporting at national and supra-national level (e.g. to the European Centre for Diseases Prevention and Control, ECDC) derives from many factors. In Europe, CE notification requirements vary and are applied differently from country to country \[[@CR5]\]. Further, the origin and type of available official data is heterogeneous (case-based or aggregated, from laboratories or hospitals or physicians), derived mainly from hospitalization records \[[@CR5]--[@CR8]\]. Patients managed as outpatients are largely not captured by official statistics, and notification of hospital cases to a central level is often incomplete. Moreover, in official European records, species differentiation between *E. granulosus* (*s.l.*) and *Echinococcus multilocularis*, the agent of alveolar echinococcosis (AE), is limited, adding to the inaccuracy of data \[[@CR9], [@CR10]\].

Official data are collected at national and supra-national level for epidemiological purposes. Pivotal data characterizing the course and clinical decision making for the management of this complex infection, such as cyst stage, clinical management details, and outcomes, are not collected. CE is a chronic, generally low-prevalence disease with heterogeneous clinical manifestations (including cyst number, location, size, stage, symptoms, complications and so on) that develops over years and requires a very long follow-up period to ascertain the outcome of the chosen clinical management approach \[[@CR11]--[@CR13]\]. Consequently, prospective clinical trials are virtually impossible to perform and treatment recommendations are largely based on expert opinion, which are, in turn, not widely followed \[[@CR14], [@CR15]\]. This often results in the administration of inappropriate treatments, which burden both patients and health care systems \[[@CR16], [@CR17]\].

In 2012, the WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis (San Matteo Hospital Foundation, University of Pavia, Italy) and the Italian National Health Institute (Istituto Superiore di Sanità, Rome, Italy), through funding from the Sardinian Experimental Zooprophylactic Institute (Sassari, Italy), launched the Italian Register of Cystic Echinococcosis (RIEC) \[[@CR18]\]. This aimed to respond to a long-standing need for an accessible register of CE cases, built to consider the peculiar characteristics of this infection. In 2014, RIEC was restructured and expanded into the European Register of Cystic Echinococcosis (ERCE), in the context of the European FP7 project "HERACLES" \[[@CR19]\]. The main aims of the register were: (i) to indicate the magnitude of the problem represented by CE (mainly by recording cases otherwise not captured by official records, such as those only managed as outpatients); (ii) to bring the importance of CE to the attention of health authorities; (iii) to encourage public health policies for its control; and (iv) to support epidemiological, biological, and clinical research on CE by establishing a prospective case retrieval through the collection of data in a harmonized manner. Moreover, the ERCE supports the biobank repository of biological material derived from patients with CE and *E. granulosus* (*s.l.*) parasites (EchinoBioBank), established in Salamanca, Spain, in the context of the HERACLES project.

The structure and requirements of the ERCE are shown in Table [1](#Tab1){ref-type="table"} and have been described in detail in a previous publication on the first meeting of the ERCE network that took place in Rome in 2015 \[[@CR19]\]. Here, we present an overview of data present in the ERCE and discuss its future development, five years after its launch.Table 1Schematic overview of the structure and features of the ERCEItemFeaturePatients enrolled in ERCEWith confirmed or probable CE (according to WHO-IWGE 2010 Expert Consensus definition)In- and out-patientsAll ages and both sexesDiagnosed at the time of the recorded visit or previously; follow-up visitsData recorded for each patientPersonal data: year of first diagnosis of CEClinical data: cyst(s) localization, size and stageHistory of treatments and treatment/management approach currently being receivedBiological samples collected (if any)ERCE structureMulticentre database located within the secured IT network of the Italian National Institute of Health (Istituto Superiore di Sanità, ISS) in RomeCurrently available in English, Italian, Romanian, Bulgarian and TurkishOrganized in sheets where patient data are recordedEach registered patient is automatically given a unique ERCE ID codeData are uncoupled and pseudonymizedOnly the physician who entered the patient's data and the ERCE manager can access the recordERCE usersPhysicians working in health centres where patients with CE are managedJoin the ERCE network voluntarilyAre provided with personal credentials to login into the registerDifferent roles are envisaged:- the "person in charge" in each centre enters patients' data- the "supervisor" in each centre can read only data of his/her centre- the Register "coordinator" has access to and can download data from all national centresPossibility to have a National Centre coordinating data collection from centres of the Country^a^Requirements to join ERCETo be a physician working in centres where CE patients (in- and out-patients) are visitedTo obtain the approval from the ethics committee of each centre/country involved (although the implementation of the Register is only observational and does not involve clinical experimentation)Ownership of dataData from individual centres belong to the individual centres themselvesThe coordinator can only use cumulative data for periodic presentations on the progress of the ERCEPublication of data requires the consent of the individual centresConfidentiality and securityERCE was approved by the ISS ethics committee (Prot. PRE-C-915/14 of November 25th, 2014), extending the agreement to the Italian Register of CE (Ns Prot. CE/12/347 of May 7th, 2012)ERCE complies with EU Regulation on the protection and use of personal data (Reg. EU 2016/679)Two informed consent forms must be signed by patients at initial registration to allow:- their data to be recorded in the Register- their biological samples to be shipped to the Echino-BiobankThe ISS datacentre, through the Azure Backup Server System, makes a complete backup every night and an online backup copy on cloud daily, weekly, monthly and yearly, stored for up to 20 years^a^France and Iran

Methods {#Sec2}
=======

The complete ERCE database explored on March 31st 2019. Analysed data referred to participating centres (number, country, date of joining the ERCE network, centre's activity identified as recording of visits in the previous 18 months, total recorded cases and follow-up visits), and registered cases (sex, age, country of birth, cysts characteristics and clinical management at each visit). For the analysis of clinical management, only the data of patients whose records included cyst stage, location, and clear indication of management at defined visits, occurring after the date of first recording in ERCE, were extrapolated from the database. The descriptive analysis of the stage-specific management of CE was carried out as if each observation of the set "cyst stage-location-management" was an independent observation. That is, an individual cyst in a given localization in a patient, which was observed N times in different cyst stage and/or assigned to a different clinical management option, was analysed here as "N observations". Only when a change in cyst stage and/or management allocation was recorded, a new observation was scored. Data were summarized as counts and percentages.

Results {#Sec3}
=======

On March 31st 2019, 44 centres from 15 countries (Fig. [1](#Fig1){ref-type="fig"}), seven of which are non-European, were affiliated to ERCE. Centres joining the ERCE steadily increased over the years (Fig. [2](#Fig2){ref-type="fig"}). Of the affiliated centres, 34 (77%) registered at least one patient and, of these, 18 (53%) recorded at least one visit within the past 18 months (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). The absence of data from those centres that never entered patients' information in the database (Fig. [2](#Fig2){ref-type="fig"}) is most likely due to a variable combination of reasons. These include absence of new diagnoses of CE or follow-up visits of patients managed in the centre (especially in hospitals that are not referral centres for CE or that joined the register only very recently), duties overload or change of position of the clinician who originally joined voluntarily the network.Fig. 1Countries and number of centres involved in the ERCE. Only the centres that registered at least one patient are includedFig. 2Affiliation and current activity of the ERCE network centres. Bars represent the cumulative number of affiliated centres at each year of activity of the RIEC (2012--2013) and ERCE (2014 onwards). Current activity status of affiliated centres is shown in the 2019 bar. Light grey indicates centres that never entered patients' information in the database; white indicates 3 centres in France that send their data to a National reference centre which entered these patients' information in the database; dark grey indicates centres that entered at least 1 patients' information in the database since their affiliation but did not enter new data in the past 18 months; black indicates centres that entered new patients' information in the database in the past 18 months

A total of 2097 patients were registered at the date of data extraction; of these, 831 (40%) were registered in 16 Italian centres (Fig. [3](#Fig3){ref-type="fig"}). Notably, a total of 119 patients (5.7% of all patients registered in ERCE) were detected during the ultrasound-based population screening carried out in 2014--2015 in Bulgaria, Romania and Turkey, in the context of the HERACLES project \[[@CR20]\]. These patients are 12.2% of those registered in Sofia (Bulgaria), 9.6% of those registered in Bucharest (Romania), and 45.3% of those registered in Ankara (Turkey). The distribution of patients by sex and age at first registration in the ERCE is shown in Fig. [4](#Fig4){ref-type="fig"}; 53.1% of patients were females and 46.9% males, showing this even distribution between sexes throughout all age groups, most patients (66.4%) were in the adult 30--69 years age group (mean age 46.20 years, range 2--97 years). Additional file [1](#MOESM1){ref-type="media"}: Table S1 shows the country of birth of registered patients. Immigrants (defined as patients with CE who were born in a country different to that of enrolment), constituted 19.9% of the total registered patients; however, their relative percentage by centre, unsurprisingly, varied greatly among centres.Fig. 3Number of patients in the ERCE by country of registrationFig. 4Age groups and sex of patients registered in the ERCE

Echinococcal cyst characteristics (organ involved and/or cyst stage) were reported by 28 centres (representing 82.4% of centres having registered at least one patient) at least in one visit for at least one cyst in 1643 (78.3%) of patients. Although cyst staging according to the WHO-IWGE (Informal Working Group on Echinococcosis) classification \[[@CR14]\] was used by 27 centres (i.e. 79.4% of centres having registered at least one patient); however, cyst stage, when applicable, was not constantly reported in all patients registered in individual centres and/or at each visit of the same patient. At first registration, for example, cyst staging was not reported for one-third of registered cysts (Table [2](#Tab2){ref-type="table"}).Table 2Cyst characteristics at first registration in the ERCE (for the subset of patients for whom these data were recorded by the data entering clinician)No. of cysts per patient^a^\
(*N* = 1966)No. of patients (%)WHO-IWGE stageLiver right lobe (%)Liver left lobe (%)Liver both lobes (%)Lung right (%)Lung left (%)Lung both (%)Other localizations (%)Total (%)11162 (59.1)Not specified342 (16.9)115 (23.9)26 (47.3)279 (86.9)224 (89.6)21 (80.8)77 (30.1)1084 (31.8)2380 (19.3)CE1325 (16.1)65 (13.5)3 (5.4)13 (4.0)8 (3.2)2 (7.7)48 (18.8)464 (13.6)3136 (6.9)CE2190 (9.4)44 (9.1)5 (9.1)5 (1.6)4 (1.6)024 (9.4)272 (8.0)448 (2.4)CE3a133 (6.6)30 (6.2)3 (5.4)6 (1.9)3 (1.2)06 (2.3)181 (5.3)523 (1.2)CE3b199 (9.8)45 (9.4)6 (10.9)2 (0.6)0031 (12.1)283 (8.3)610 (0.5)CE4478 (23.6)105 (21.8)3 (5.4)8 (2.5)6 (2.4)2 (7.7)39 (15.3)641 (18.8)77 (0.4)CE5201 (9.9)31 (6.5)04 (1.2)2 (0.8)018 (7.1)256 (7.5)8191≥ 1017 (0.9)CL33 (1.6)15 (3.1)3 (5.4)1 (0.3)01 (3.8)6 (2.3)59 (1.7)CL27 (1.4)Post-surgery120 (5.9)31 (6.5)6 (10.9)3 (0.9)3 (1.2)06 (2.3)169 (5.0)Post-surgery153 (7.8)Total2021 (59.7)481 (14.2)55 (1.6)321 (9.5)250 (7.4)26 (0.8)255 (7.5)3409^a^At enrolment*Abbreviations*: CL, cystic lesion (suspect cyst according to the WHO-IWGE)

At first registration in ERCE, the majority (*n* = 1162/1966; 59.1%) of patients who had information on cyst number recorded had a single cyst; 153 (7.8%) had no cysts and were registered as patients with only post-surgical cavities/scars (Table [2](#Tab2){ref-type="table"}). In total, 3409 cysts were recorded at first registration; the most frequent localization was the liver (*n* = 2557 cysts; 75.5%), followed by the lungs (*n* = 597 cysts; 17.5%) (Table [2](#Tab2){ref-type="table"}). Other localizations, accounting for 7.5% of recorded cysts, included abdominal cavity, bone, central nervous system, heart, kidneys, muscle, pancreas, pelvis, skin and subcutaneous tissue, and spleen; 78 (3.9%) patients had cysts in more than one organ. Table [2](#Tab2){ref-type="table"} also summarizes the distribution of cyst stages recorded at first registration, classified according to the WHO-IWGE classification \[[@CR14]\].

Treatments carried out prior to ERCE registration, as well as clinical management upon registration and subsequent follow-up visits, are also recorded in the register. Seventeen centres (representing 50.0% of centres having registered at least one patient) recorded at least once one follow-up visit for at least one patient; in these centres, 435 patients had at least one follow-up visit recorded (a median of 21% patients per centre, ranging from 1.6% to 84.2%). Data concerning the clinical management of patients could be analysed for 523 patients registered in 24 centres, for 726 cysts. As 82 patients had at least one follow-up visit recorded in which a change in cyst stage and/or management allocation was indicated, the total number of "cyst stage-location-management" observations analysed was 920 (Additional file [1](#MOESM1){ref-type="media"}: Table S2). A stage-specific approach is recommended by the WHO-IWGE for asymptomatic CE cysts of the liver. We analysed the data concerning the clinical approach of hepatic cysts according to cyst stage. Results are summarized in Table [3](#Tab3){ref-type="table"}. These results need to be evaluated while acknowledging the fact that no information is recoded in the ERCE register concerning symptoms or other clinical factors that may induce the treating physician to deviate from the recommended stage-specific approach. The clinical management used for cysts in other organs is summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S2. One centre from a non-European country, systematically did not indicate any cyst stage and all cases were managed surgically, with no indication of associated albendazole prophylaxis in the virtual totality of cases.Table 3Clinical management approach of hepatic CE cysts by stageStage*N*^a^ABZSurgery with no specification of prophylaxis with ABZSurgery with specified associated prophylaxis with ABZPercutaneous treatment with no specification of prophylaxis with ABZPercutaneous treatment with specified associated prophylaxis with ABZWatch-and-waitCE115966351912252CE2100412221015^b^1CE3a94415621129CE3b210834600459CE4-CE521017^c^21400177^a^Number of "cyst stage-location-management" observations^b^11 cysts in the CE2 stage were treated by percutaneous treatment plus ABZ in the Turkish center where the non-PAIR percutaneous technique is performed, as envisaged by the WHO-IWGE expert consensus^c^For 6 CE4 cysts, ABZ treatment was applied due to the concomitant presence of other CE cyst stages*Abbreviation*: ABZ, albendazole

Discussion {#Sec4}
==========

The primary aim of the ERCE, at its launch, was prominently of a public health perspective, to indicate to stakeholders the magnitude of the problem represented by CE and its underreporting, through the recording of cases not captured by official records \[[@CR19]\]. Since its launch, new centres are joining the ERCE over time, demonstrating that CE, although neglected, is of interest for clinicians diagnosing and managing patients with CE, in European and non-European countries alike. In the time between data analysis and the writing of this paper, a 45th centre, in Afghanistan, joined the ERCE. This is of particular interest because no epidemiological data on CE are available in this country, published data being limited to case reports of patients from Afghanistan diagnosed in other countries \[[@CR3]\]. In our cohort described here, 39 patients from Afghanistan were recorded in Iran and Austria ERCE-affiliated centres (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Data collected in the ERCE, therefore, could highlight the neglected status of CE in endemic countries and constitute an important starting point to tackle this problem.

Since joining the register and recording of patients is voluntary and relies entirely on the time and goodwill of single clinicians, it is difficult to compare the figures recorded in the ERCE with those of official records. However, data collected in the ERCE show that a proportion of patients reaching medical attention are indeed managed with approaches not requiring hospitalization, and are therefore largely not captured by those notification systems which are based only on hospital discharge records \[[@CR21]\]. We found, unsurprisingly, that a variable proportion of patients originate from countries different from the country of registration, both within and outside Europe. The increase of the migration phenomenon at global level \[[@CR22]\] seems to cause an increase in CE cases seen in non-endemic areas \[[@CR23]\] as well as an additional burden in CE-endemic countries. The ERCE could be, therefore, a useful tool to complement hospital-derived data, to obtain a better picture of the epidemiological situation of clinical CE and support public health analyses and planning of targeted interventions. Furthermore, the ERCE aims to capture only probable or confirmed CE cases, based on the current definition of the WHO-IWGE \[[@CR14]\], with diagnosis based on the visualization on imaging of a lesion with features compatible with or pathognomonic of CE. This is different from the case definition of "echinococcosis" adopted at national and supra-national level in Europe, as currently official data not only do not distinguish between cases of CE and AE, but also allow patients positive solely on serology but with no evidence of actual cysts, to be recorded as "confirmed echinococcosis" cases \[[@CR10]\].

In contrast to official data reports, the ERCE has been structured to collect prospectively and in a harmonized manner several clinical features of CE cases over follow-up visits. CE is a generally low-prevalence, chronic infection with extremely variable clinical presentations; it cannot be managed using a "one-fits-all" approach, and years-long follow-up is required to ascertain the outcome of any clinical management approach. As a result, prospective clinical trials are extremely difficult to conduct. The WHO-IWGE encouraged the clinical community to join shared data platforms to collect prospectively and analyse highly standardized clinical data as, in such a situation, it is possible to obtain valid comparisons of different treatments using data from observational studies, provided specific prerequisites are fulfilled \[[@CR24]\]. The ERCE can thus be a valuable template from which further tailoring a tool fulfilling these prerequisites, to accomplish this ambitious goal.

At the time of the present analysis, it was possible to evaluate the matching cyst characteristics-management option only for about 25% of patients. On the one hand, this highlights the problem of suboptimal data completeness and quality, which derives from the voluntary nature of adherence to and feeding data into the register. On the other hand, this result may also have its roots in the scarce knowledge and application of the CE cyst staging system and the stage-specific clinical management approach recommended by the WHO-IWGE \[[@CR13], [@CR14]\]. This is exemplified by the case of one centre in a non-European country, where, systematically, no cyst stage was ever indicated, and all cases were reported to have been managed surgically. Although many variables, other than cyst stage, that may influence a physician to choose a treatment option, are not currently captured in the ERCE, where cyst staging is being used at least some stage-specific approaches seem to be applied. For example, the "watch and wait" approach was reported for over 80% of the observations concerning hepatic inactive (CE4-CE5) cysts. It is plausible to deduce that knowledge of cyst staging and applying the stage-specific approach are mutually related.

The ERCE, as it stands, suffers from several critical issues, especially regarding data quality and completeness, which will be addressed in the future, to fulfil the aims envisioned above. As mentioned, the voluntary nature of joining the register, and the reliance on the motivation of single clinicians to enter data for a period of long time, condition the variable quality of the entered data. However, additional informatics tools may be introduced to foster the accuracy and completeness of data entered, such as automatic crosschecking of data for incongruences. In addition, the option to upload cyst images should be implemented, to validate data before comparisons of different treatments is attempted. Finally, other prognostic factors relevant to treatment outcomes must be included, to allow drawing evidences from such case series.

Conclusions {#Sec5}
===========

To conclude, the ERCE achieved its goal in showing that CE is a neglected but relevant public health problem in Europe and beyond, as indicated by the data collected so far and by the growing interest shown by European and non-European clinicians. Current data collected in the ERCE highlight the need for the development and implementation of a better notification system, at least at the European level, without which a realistic picture of the prevalence and burden of human CE cannot be achieved. In addition, the ERCE appears a valuable starting platform to draw future evidence-based recommendations, overcoming the virtual impossibility to perform clinical trials on CE \[[@CR24]\]. The need to enter CE cyst stages and clinical management decisions may also constitute a vehicle of knowledge of the WHO-IWGE staging and recommendations among the clinician's community.

Learning from the past five years, in the near future the ERCE will be expanded to the online International Register of CE (IRCE) within the framework of the "PERITAS" project funded by the European platform EU-LAC Health (<http://eulachealth.eu/>) and the National funding agencies of the participating institutions. The ERCE will be restructured into the IRCE aiming to answer relevant questions regarding the clinical management of CE.
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**Additional file 1: Table S1.** Country of birth for patients registered in ERCE centres. **Table S2.** Clinical management of cysts by stage and location.
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